Last reviewed · How we verify

NCT02901509: QoLCHIK

Epidémie de Chikungunya à l'île de La Réunion : Effet à Dix Ans de l'Infection Sur la qualité de Vie Dans la Cohorte TELECHIK

Completed Last updated 4 September 2018
What this trial tests

trial in Chikungunya Fever in 386 participants. Completed in 31 May 2018.

Timeline
1 June 2016
Primary endpoint
31 May 2018
31 May 2018

Quick facts

Lead sponsorCentre Hospitalier Universitaire de la Réunion
StatusCompleted
Study typeOBSERVATIONAL
Enrollment386
Start date1 June 2016
Primary completion31 May 2018
Estimated completion31 May 2018
Sites1 location across France

Conditions studied

Sponsor

Centre Hospitalier Universitaire de la Réunion

Who can join

Adults 18 to 85, any sex, with Chikungunya Fever or Quality of Life. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

QoLCHIK study aims at evaluating impact of chikungunya infection on the quality of life of infected people during the 2005-2006 outbreak in Reunion Island and followed in the TELECHIK cohort by comparing scores of SF-36 health survey.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Chikungunya Fever

Currently open trials in the same condition.

Other Centre Hospitalier Universitaire de la Réunion trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02901509.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing